Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Blinatumomab added to chemotherapy improves disease-free survival in newly diagnosed NCI standard risk paediatric B-ALL

Dr Rachel Rau - University of Washington, Seattle, USA
Blinatumomab added to chemotherapy improves disease-free survival in newly diagnosed NCI standard risk paediatric B-ALL ( Dr Rachel Rau - University of Washington, Seattle, USA )
16 Dec 2024

Demographics, characteristics, survival and outcomes in older, untreated, AML with NPM1 mutations or KMT2A rearrangements

Dr Ashley Yocum - Leukemia & Lymphoma Society, New York, USA
Demographics, characteristics, survival and outcomes in older, untreated, AML with NPM1 mutations or KMT2A rearrangements ( Dr Ashley Yocum - Leukemia & Lymphoma Society, New York, USA )
16 Dec 2024

Guiding metastasis-directed therapy with different PET/CT radiotracers affects distant disease control in HSPC patients

Dr Francesco Lanfranchi - University of Genoa, Genoa, Italy
Guiding metastasis-directed therapy with different PET/CT radiotracers affects distant disease control in HSPC patients ( Dr Francesco Lanfranchi - University of Genoa, Genoa, Italy )
13 Dec 2024

Bladder cancer updates from the second half of 2024

Prof Alison Birtle, Dr Ignacio Durán and Dr Félix Guerrero-Ramos
Bladder cancer updates from the second half of 2024 ( Prof Alison Birtle, Dr Ignacio Durán and Dr Félix Guerrero-Ramos )
29 Nov 2024

30 minute infusion of isatuximab shows potential in newly diagnosed multiple myeloma

Prof Philippe Moreau - University Hospital of Nantes, Nantes, France
30 minute infusion of isatuximab shows potential in newly diagnosed multiple myeloma ( Prof Philippe Moreau - University Hospital of Nantes, Nantes, France )
25 Nov 2024

EMUC 2024: Optimising strategies in mHSPC and mCRPC

Prof Gerhardt Attard, Prof Wolfgang Fendler, Dr Lynda Corrigan, Prof Jochen Walz
EMUC 2024: Optimising strategies in mHSPC and mCRPC ( Prof Gerhardt Attard, Prof Wolfgang Fendler, Dr Lynda Corrigan, Prof Jochen Walz )
13 Nov 2024

SIOG 2024: Updates in haematology

Dr Ashley Rosko - The Ohio State University, Columbus, USA
SIOG 2024: Updates in haematology ( Dr Ashley Rosko - The Ohio State University, Columbus, USA )
1 Nov 2024

CDK4/6 inhibitors and endocrine therapy in elderly female patients with advanced hormone receptor positive HER-2 negative BC

Dr Renu Ragupathi - University Hospitals Dorset, Bournemouth, UK
CDK4/6 inhibitors and endocrine therapy in elderly female patients with advanced hormone receptor positive HER-2 negative BC ( Dr Renu Ragupathi - University Hospitals Dorset, Bournemouth, UK )
1 Nov 2024

Understanding the remaining unmet needs in a post ASCT NDMM setting

Dr Fredrik Schjesvold - Oslo Myeloma Center, Oslo, Norway
Understanding the remaining unmet needs in a post ASCT NDMM setting ( Dr Fredrik Schjesvold - Oslo Myeloma Center, Oslo, Norway )
31 Oct 2024

ESMO and WCLC: Latest developments in EGFR mutated NSCLC

Dr Matthew Krebs, Dr Antonio Passaro, Dr Enriqueta Felip and Prof Pascale Tomasini
ESMO and WCLC: Latest developments in EGFR mutated NSCLC ( Dr Matthew Krebs, Dr Antonio Passaro, Dr Enriqueta Felip and Prof Pascale Tomasini )
18 Oct 2024

Choosing the right Tyrosine Kinase Inhibitors (TKI) for CML Patients

Dr Prashant Mehta - Amrita Hospital, Karala, India
Choosing the right Tyrosine Kinase Inhibitors (TKI) for CML Patients ( Dr Prashant Mehta - Amrita Hospital, Karala, India )
10 Oct 2024

Advancements in head and neck cancer treatment in India

Dr Amol Akhade - Tata Memorial Hospital, Mumbai, India
Advancements in head and neck cancer treatment in India ( Dr Amol Akhade - Tata Memorial Hospital, Mumbai, India )
10 Oct 2024